Cite
HARVARD Citation
Sakata, Y. et al. (2021). Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT). European journal of cancer. pp. 144-153. [Online].